The team 2 activities are organized according to three main axis of research, 1- Development and realization of skin cancer clinical trials, 2- Translational research, focusing mainly on investigation of melanoma microenvironment and 3- Epidemiology and prevention of melanoma and non-melanoma skin cancer.
1. Development and realization of skin cancer clinical trials
The team developed institutional clinical research focusing on melanoma: adoptive transfer of TIL in adjuvant setting and specific T cells in metastatic stage. The clinical team collaborated also to other national and European academic clinical trials. The clinical research is also dedicated to the development of new drugs and cell therapy in melanoma and non-melanoma skin cancer in collaboration with pharmaceutical industry (Roche, BMS, GSK, Transgene…).
In order to promote transnational research, optimize the achievement of clinical trials and to support basic research, team 2 coordinates since 2010 a national clinical database (RIC-Mel) of the GMFMel Network.
2. Translational research, focusing mainly on investigation of melanoma microenvironment
From the clinical activities, we established a tissue bank (1130 tumor samples, 190 melanoma cell lines and 450 batches of TILs). This tissue bank constitutes the basis of a collaborative work with other teams. The team 2 translational research is based on the identification of prognostic markers in the tumor microenvironment. The aim of this work is to identify different evolutionary patterns of patients corresponding to several subtypes of melanoma. In this field, we characterize melanoma tumor cell lines and the corresponding tumor samples, at several levels: Analysis of gene mutations such as BRAF, cKIT, MEK, NRAS and HRAS; study of the expression level of melanoma tumor antigens; analysis of the production of cytokines and chemokines involved in the regulation of tumor microenvironment.
3. Epidemiology and prevention of melanoma and non-melanoma skin cancer
The third main axis of the team 2 activity is epidemiology and prevention of skin cancer. We constructed a strategy to assess the efficacy of a strategy of melanoma targeted screening which has led to development of an individual score of melanoma risk factors: the Self-Assessment of Melanoma Risk Score (SAMScore).
The epidemiological team established a large cohort of 3923 of patients at high risk of melanoma (COPARIME Cohort, INCa Grant). Thanks to this cohort, the goal of this team is to inestigate the early detection approaches, to promote melanoma prevention, to ensure the training of general practitioners on patient prevention.
B. Dréno, PU-PH
M. Denis, PU-PH
S. Corvec, MCU-PH
JM Nguyen, MCU/PH
C. Rat, MCU/PH
M. Saint-Jean, PH
L. Peuvrel, PH
A. Khammari, IRC – CHU
J. Cassecuel, ARC CDD CHU
C. Dabrowski, ARC CDD CHU
T. Louadj, ARC CDD CHU
A. Boisrobert, ARC CHU
M. Saignes, ARC CHU
C. Frénard, CCA CHU
E. Varey, ARC CDD CHU
JX. Lemauft, CRA
M. Le Moigne, Doctorant
MA. Dagnelie, Doctorant
AC. Knol, IR CHU
MC. Pandolfino, IR CHU
O. Nerriere, IR CDD CHU
A. Vallee IR CDI CHU
S. Charpentier, IR CHU
C. Leroy, TR CDI CHU
A. Mordelet, TR CDD CHU
A. Daminette, TR CDD CHU
S. Le Naour, Master2
1. Chapman PB, et al. BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. (2011)
2. Saint-Jean M, et al. Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy? J Invest Dermatol. (2014)
3. Dreno B, Basset-Seguin N, Caro I, Yue H, Schadendorf D. Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma. Oncologist. (2014)
4. Khammari A, et al. Adoptive TIL transfer in the adjuvant setting for melanoma: long-term patient survival. J Immunol Res. (2014)
5. Khammari A, Nguyen JM, Saint-Jean M, Knol AC, Pandolfino MC, Quereux G, Brocard A, Peuvrel L, Saiagh S, Bataille V, Limacher JM, Dreno B. Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-γ) in metastatic melanoma patients. Cancer Immunol Immunother. (2015)